Dawn Bassett

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Yun Yen, Glen J. Weiss, Mark E. Davis, 2013, Investigational New Drugs.